{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T21:38:26Z","timestamp":1788903506247,"version":"build-2803163510"},"reference-count":114,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,21]],"date-time":"2017-04-21T00:00:00Z","timestamp":1492732800000},"content-version":"vor","delay-in-days":20,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","cancertreatmentreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.ctrv.2016.11.011","type":"journal-article","created":{"date-parts":[[2017,3,2]],"date-time":"2017-03-02T21:19:17Z","timestamp":1488489557000},"page":"107-119","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":116,"special_numbering":"C","title":["GEIS guidelines for gastrointestinal sarcomas (GIST)"],"prefix":"10.1016","volume":"55","author":[{"given":"Andr\u00e9s","family":"Poveda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Garc\u00eda del Muro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Antonio","family":"L\u00f3pez-Guerrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Cubedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9sar","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Valverde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Mart\u00edn-Broto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ctrv.2016.11.011_b0005","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.crad.2003.10.018","article-title":"Imaging of gastrointestinal stromal tumour (GIST)","volume":"59","author":"Lau","year":"2004","journal-title":"Clin Radiol"},{"issue":"15_suppl","key":"10.1016\/j.ctrv.2016.11.011_b0010","first-page":"10506","article-title":"A phase 2 study of ponatinib in patients (pts) with advanced gastrointestinal stromal tumors (GIST) after failure of tyrosine kinase inhibitor (TKI) therapy: Initial report","volume":"32","author":"Heinrich","year":"2014","journal-title":"ASCO Meet Abstr"},{"key":"10.1016\/j.ctrv.2016.11.011_b0015","doi-asserted-by":"crossref","unstructured":"Demetri GD, von Mehren M, Antonescu CR, DeMatteo RP, Ganjoo KN, Maki RG, et al. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compreh Cancer Network: JNCCN 2010; Suppl 2: S1-41; quiz S2-4. PubMed PMID: 20457867.","DOI":"10.6004\/jnccn.2010.0116"},{"issue":"16","key":"10.1016\/j.ctrv.2016.11.011_b0020","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.3748\/wjg.v10.i16.2417","article-title":"Gastrointestinal stromal tumor: computed tomographic features","volume":"10","author":"Lee","year":"2004","journal-title":"World J Gastroenterol: WJG"},{"issue":"Suppl 5","key":"10.1016\/j.ctrv.2016.11.011_b0025","doi-asserted-by":"crossref","first-page":"v98","DOI":"10.1093\/annonc\/mdq208","article-title":"Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Casali","year":"2010","journal-title":"Ann Oncol: Off J Eur Soc Med Oncol\/ESMO"},{"issue":"2","key":"10.1016\/j.ctrv.2016.11.011_b0030","doi-asserted-by":"crossref","first-page":"152","DOI":"10.5946\/ce.2015.48.2.152","article-title":"Yields and Utility of Endoscopic Ultrasonography-Guided 19-Gauge Trucut Biopsy versus 22-Gauge Fine Needle Aspiration for Diagnosing Gastric Subepithelial Tumors","volume":"48","author":"Na","year":"2015","journal-title":"Clin Endos"},{"issue":"2","key":"10.1016\/j.ctrv.2016.11.011_b0035","doi-asserted-by":"crossref","first-page":"E161","DOI":"10.1055\/s-0034-1391671","article-title":"Usefulness of endoscopic ultrasound-guided fine-needle aspiration with a forward-viewing and curved linear-array echoendoscope for small gastrointestinal subepithelial lesions","volume":"3","author":"Yamabe","year":"2015","journal-title":"Endosc Int Open"},{"issue":"8","key":"10.1016\/j.ctrv.2016.11.011_b0040","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1007\/s00464-012-2186-7","article-title":"Laparoscopic resection of gastric gastrointestinal stromal tumors (GIST) is safe and effective, irrespective of tumor size","volume":"26","author":"De Vogelaere","year":"2012","journal-title":"Surg Endosc"},{"key":"10.1016\/j.ctrv.2016.11.011_b0045","unstructured":"Cho JW, Korean ESDSG. Current Guidelines in the Management of Upper Gastrointestinal Subepithelial Tumors. Clin Endos 2016; Feb 22. PubMed PMID: 26898512."},{"issue":"1","key":"10.1016\/j.ctrv.2016.11.011_b0050","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s10120-015-0526-8","article-title":"The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines","volume":"19","author":"Nishida","year":"2016","journal-title":"Gastric Cancer: Off J Int Gastric Cancer Assoc Japanese Gastric Cancer Assoc"},{"issue":"1","key":"10.1016\/j.ctrv.2016.11.011_b0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s004280000338","article-title":"Gastrointestinal stromal tumors\u2013definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis","volume":"438","author":"Miettinen","year":"2001","journal-title":"Virchows Archiv: Int J Pathol"},{"issue":"10","key":"10.1016\/j.ctrv.2016.11.011_b0060","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1097\/01.pas.0000172190.79552.8b","article-title":"Gastrointestinal stromal tumors of the stomach in children and young adults: a clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases with long-term follow-up and review of the literature","volume":"29","author":"Miettinen","year":"2005","journal-title":"Am J Surg Pathol"},{"issue":"Suppl 5","key":"10.1016\/j.ctrv.2016.11.011_b0065","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/S0959-8049(02)80602-5","article-title":"Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review","volume":"38","author":"Miettinen","year":"2002","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2016.11.011_b0070","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1365-2559.2005.02291.x","article-title":"Gastrointestinal stromal tumours: an update","volume":"48","author":"Rubin","year":"2006","journal-title":"Histopathology"},{"issue":"18","key":"10.1016\/j.ctrv.2016.11.011_b0075","doi-asserted-by":"crossref","first-page":"5715","DOI":"10.1158\/1078-0432.CCR-08-0622","article-title":"Multiple primary sporadic gastrointestinal stromal tumors in the adult: an underestimated entity","volume":"14","author":"Gasparotto","year":"2008","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"issue":"10","key":"10.1016\/j.ctrv.2016.11.011_b0080","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.5858\/2006-130-1466-GSTROM","article-title":"Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis","volume":"130","author":"Miettinen","year":"2006","journal-title":"Arch Pathol Lab Med"},{"issue":"12","key":"10.1016\/j.ctrv.2016.11.011_b0085","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.3748\/wjg.v9.i12.2809","article-title":"Clinical manifestations and prognostic factors in patients with gastrointestinal stromal tumors","volume":"9","author":"Lin","year":"2003","journal-title":"World J Gastroenterol: WJG"},{"issue":"5","key":"10.1016\/j.ctrv.2016.11.011_b0090","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1053\/hupa.2002.123545","article-title":"Diagnosis of gastrointestinal stromal tumors: a consensus approach","volume":"33","author":"Fletcher","year":"2002","journal-title":"Hum Pathol"},{"issue":"2","key":"10.1016\/j.ctrv.2016.11.011_b0095","doi-asserted-by":"crossref","first-page":"165","DOI":"10.5858\/134.2.165","article-title":"Protocol for the examination of specimens from patients with gastrointestinal stromal tumor","volume":"134","author":"Rubin","year":"2010","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.ctrv.2016.11.011_b0100","doi-asserted-by":"crossref","unstructured":"Group ESESNW. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol: Off J Eur Soc Med Oncol\/ESMO 2014;25 Suppl 3: iii21-6. PubMed PMID: 25210085.","DOI":"10.1093\/annonc\/mdu255"},{"issue":"3","key":"10.1016\/j.ctrv.2016.11.011_b0105","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1365-2559.2008.02977.x","article-title":"Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours","volume":"53","author":"Lasota","year":"2008","journal-title":"Histopathology"},{"issue":"3","key":"10.1016\/j.ctrv.2016.11.011_b0110","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/PAS.0b013e318186b158","article-title":"Monoclonal antibody DOG1.1 shows higher sensitivity than KIT in the diagnosis of gastrointestinal stromal tumors, including unusual subtypes","volume":"33","author":"Liegl","year":"2009","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.ctrv.2016.11.011_b0115","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1073\/pnas.1009199108","article-title":"Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations","volume":"108","author":"Janeway","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"10.1016\/j.ctrv.2016.11.011_b0120","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/path.1546","article-title":"Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity","volume":"202","author":"Debiec-Rychter","year":"2004","journal-title":"J Pathol"},{"issue":"7","key":"10.1016\/j.ctrv.2016.11.011_b0125","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1097\/00000478-200407000-00007","article-title":"KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications","volume":"28","author":"Medeiros","year":"2004","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/j.ctrv.2016.11.011_b0130","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/PAS.0b013e31826c1761","article-title":"Dedifferentiation in gastrointestinal stromal tumor to an anaplastic KIT-negative phenotype: a diagnostic pitfall: morphologic and molecular characterization of 8 cases occurring either de novo or after imatinib therapy","volume":"37","author":"Antonescu","year":"2013","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"10.1016\/j.ctrv.2016.11.011_b0135","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/j.semdp.2006.09.001","article-title":"Gastrointestinal stromal tumors: pathology and prognosis at different sites","volume":"23","author":"Miettinen","year":"2006","journal-title":"Semin Diagn Pathol"},{"issue":"4","key":"10.1016\/j.ctrv.2016.11.011_b0140","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1053\/j.seminoncol.2009.06.002","article-title":"Gastrointestinal stromal tumors I: pathology, pathobiology, primary therapy, and surgical issues","volume":"36","author":"Reichardt","year":"2009","journal-title":"Semin Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2016.11.011_b0145","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1007\/s12094-010-0576-7","article-title":"Clinical implications of KIT and PDGFRA genotyping in GIST","volume":"12","author":"Martin-Broto","year":"2010","journal-title":"Clin Transl Oncol: Off Publ Feder Spanish Oncol Soc Natl Cancer Instit Mexico"},{"key":"10.1016\/j.ctrv.2016.11.011_b0150","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3389\/fmed.2014.00043","article-title":"Gastrointestinal stromal tumor - an evolving concept","volume":"1","author":"Tornillo","year":"2014","journal-title":"Front Med"},{"key":"10.1016\/j.ctrv.2016.11.011_b0155","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1146\/annurev.pathmechdis.3.121806.151538","article-title":"Molecular pathobiology of gastrointestinal stromal sarcomas","volume":"3","author":"Corless","year":"2008","journal-title":"Ann Rev Pathol"},{"issue":"9574","key":"10.1016\/j.ctrv.2016.11.011_b0160","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/S0140-6736(07)60780-6","article-title":"Gastrointestinal stromal tumour","volume":"369","author":"Rubin","year":"2007","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.ctrv.2016.11.011_b0165","doi-asserted-by":"crossref","first-page":"6190","DOI":"10.1200\/JCO.2005.19.554","article-title":"Deletions affecting codons 557\u2013558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS)","volume":"23","author":"Martin","year":"2005","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"18","key":"10.1016\/j.ctrv.2016.11.011_b0170","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.1200\/JCO.2004.05.140","article-title":"Biology of gastrointestinal stromal tumors","volume":"22","author":"Corless","year":"2004","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2016.11.011_b0175","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S0002-9440(10)64623-8","article-title":"Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of 200 cases","volume":"157","author":"Lasota","year":"2000","journal-title":"Am J Pathol"},{"issue":"9","key":"10.1016\/j.ctrv.2016.11.011_b0180","first-page":"3329","article-title":"Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors","volume":"9","author":"Antonescu","year":"2003","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"issue":"23","key":"10.1016\/j.ctrv.2016.11.011_b0185","doi-asserted-by":"crossref","first-page":"5357","DOI":"10.1200\/JCO.2005.14.068","article-title":"PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib","volume":"23","author":"Corless","year":"2005","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2016.11.011_b0190","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1007\/s12032-011-0074-y","article-title":"Frequencies of KIT and PDGFRA mutations in the MolecGIST prospective population-based study differ from those of advanced GISTs","volume":"29","author":"Emile","year":"2012","journal-title":"Med Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2016.11.011_b0195","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1136\/jcp.2009.064550","article-title":"V600E BRAF mutations are alternative early molecular events in a subset of KIT\/PDGFRA wild-type gastrointestinal stromal tumours","volume":"62","author":"Agaimy","year":"2009","journal-title":"J Clin Pathol"},{"issue":"1","key":"10.1016\/j.ctrv.2016.11.011_b0200","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/ejhg.2013.80","article-title":"Analysis of all subunits, SDHA, SDHB, SDHC, SDHD, of the succinate dehydrogenase complex in KIT\/PDGFRA wild-type GIST","volume":"22","author":"Pantaleo","year":"2014","journal-title":"Eur J Human Genet: EJHG"},{"key":"10.1016\/j.ctrv.2016.11.011_b0205","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.biocel.2014.05.033","article-title":"Succinate dehydrogenase deficient gastrointestinal stromal tumors (GISTs) - a review","volume":"53","author":"Miettinen","year":"2014","journal-title":"Int J Biochem Cell Biol"},{"issue":"2","key":"10.1016\/j.ctrv.2016.11.011_b0210","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1365-2559.2005.02061.x","article-title":"PDGFRalpha- and c-kit-mutated gastrointestinal stromal tumours (GISTs) are characterized by distinctive histological and immunohistochemical features","volume":"46","author":"Pauls","year":"2005","journal-title":"Histopathology"},{"issue":"3","key":"10.1016\/j.ctrv.2016.11.011_b0215","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0016-5085(03)01046-1","article-title":"Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors","volume":"125","author":"Hirota","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ctrv.2016.11.011_b0220","doi-asserted-by":"crossref","unstructured":"Wasag B, Debiec-Rychter M, Pauwels P, Stul M, Vranckx H, Oosterom AV, et al. Differential expression of KIT\/PDGFRA mutant isoforms in epithelioid and mixed variants of gastrointestinal stromal tumors depends predominantly on the tumor site. Modern Pathol: Off J United States Can Acad Pathol, Inc. 2004; 17(8): 889\u201394. PubMed PMID: 15154005.","DOI":"10.1038\/modpathol.3800136"},{"issue":"1","key":"10.1016\/j.ctrv.2016.11.011_b0225","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/PAS.0b013e3181c20f4f","article-title":"Gastric stromal tumors in Carney triad are different clinically, pathologically, and behaviorally from sporadic gastric gastrointestinal stromal tumors: findings in 104 cases","volume":"34","author":"Zhang","year":"2010","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.ctrv.2016.11.011_b0230","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/sj.ejhg.5201904","article-title":"Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD","volume":"16","author":"Pasini","year":"2008","journal-title":"Eur J Human Gen: EJHG"},{"key":"10.1016\/j.ctrv.2016.11.011_b0235","doi-asserted-by":"crossref","unstructured":"Gaal J, Stratakis CA, Carney JA, Ball ER, Korpershoek E, Lodish MB, et al. SDHB immunohistochemistry: a useful tool in the diagnosis of Carney-Stratakis and Carney triad gastrointestinal stromal tumors. Modern Pathol: Off J United States Can Acad Pathol, Inc. 2011; 24(1): p. 147\u201351. PubMed PMID: 20890271. Pubmed Central PMCID: 3415983.","DOI":"10.1038\/modpathol.2010.185"},{"issue":"1","key":"10.1016\/j.ctrv.2016.11.011_b0240","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/01.pas.0000176433.81079.bd","article-title":"Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases","volume":"30","author":"Miettinen","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ctrv.2016.11.011_b0245","doi-asserted-by":"crossref","first-page":"21541","DOI":"10.1038\/srep21541","article-title":"Prognostic role of microscopically positive margins for primary gastrointestinal stromal tumors: a systematic review and meta-analysis","volume":"6","author":"Zhi","year":"2016","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.ctrv.2016.11.011_b0250","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jamcollsurg.2012.05.008","article-title":"Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence","volume":"215","author":"McCarter","year":"2012","journal-title":"J Am Coll Surg"},{"issue":"10","key":"10.1016\/j.ctrv.2016.11.011_b0255","first-page":"594","article-title":"Laparoscopic resection of gastric stromal tumors","volume":"93","author":"Maghrebi","year":"2015","journal-title":"Tunis Med"},{"issue":"7","key":"10.1016\/j.ctrv.2016.11.011_b0260","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.ejso.2015.04.001","article-title":"Outcome after laparoscopic versus open wedge resection for suspected gastric gastrointestinal stromal tumors: A matched-pair case-control study","volume":"41","author":"Goh","year":"2015","journal-title":"Eur J Surg Oncol: J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"key":"10.1016\/j.ctrv.2016.11.011_b0265","unstructured":"Edge SB, American Joint Committee on Cancer., American Cancer Society. AJCC cancer staging handbook: from the AJCC cancer staging manual. 7th ed. New York: Springer; 2010. xix, 718 p."},{"issue":"11","key":"10.1016\/j.ctrv.2016.11.011_b0270","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S1470-2045(09)70242-6","article-title":"Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis","volume":"10","author":"Gold","year":"2009","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2016.11.011_b0275","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S1470-2045(11)70299-6","article-title":"Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts","volume":"13","author":"Joensuu","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2016.11.011_b0280","doi-asserted-by":"crossref","unstructured":"von Mehren M, Benjamin RS, Bui MM, Casper ES, Conrad EU, 3rd, DeLaney TF, et al. Soft tissue sarcoma, version 2.2012: featured updates to the NCCN guidelines. J Natl Compreh Cancer Network: JNCCN 2012; 10(8): p. 951\u201360. PubMed PMID: 22878820.","DOI":"10.6004\/jnccn.2012.0099"},{"issue":"6","key":"10.1016\/j.ctrv.2016.11.011_b0285","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/ijc.11323","article-title":"Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors","volume":"106","author":"Wardelmann","year":"2003","journal-title":"Int J Cancer J Int du Cancer"},{"key":"10.1016\/j.ctrv.2016.11.011_b0290","doi-asserted-by":"crossref","unstructured":"Corless CL. Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): Results of the intergroup phase III trial ACOSOG Z9001. J Clin Oncol: Off J Am Soc Clin Oncol 2010; 28: 15s (suppl; abstr 10006).","DOI":"10.1200\/jco.2010.28.15_suppl.10006"},{"issue":"23","key":"10.1016\/j.ctrv.2016.11.011_b0295","doi-asserted-by":"crossref","first-page":"6105","DOI":"10.1158\/1078-0432.CCR-14-1677","article-title":"Tumor genotype is an independent prognostic factor in primary gastrointestinal stromal tumors of gastric origin: a european multicenter analysis based on ConticaGIST","volume":"20","author":"Wozniak","year":"2014","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.ctrv.2016.11.011_b0300","doi-asserted-by":"crossref","unstructured":"Martin Broto J, Calabuig S, Rubio J, Gutierrez A, Duran J, Garcia F, et al. 1416PDINTEGRATING GENOTYPE IN RISK CLASSIFICATION FOR GIST RECURRENCE. A SPANISH GROUP FOR SARCOMA RESEARCH (GEIS) STUDY. Ann Oncol 2014; 25(suppl 4): iv495-iv596.","DOI":"10.1093\/annonc\/mdu354.5"},{"issue":"9669","key":"10.1016\/j.ctrv.2016.11.011_b0305","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0140-6736(09)60500-6","article-title":"Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial","volume":"373","author":"Dematteo","year":"2009","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.ctrv.2016.11.011_b0310","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1200\/JCO.2013.51.2046","article-title":"Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial","volume":"32","author":"Corless","year":"2014","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2016.11.011_b0315","doi-asserted-by":"crossref","unstructured":"Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D, Schutte J, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA: J Am Med Assoc 2012; 307(12): p. 1265\u201372. PubMed PMID: 22453568.","DOI":"10.1001\/jama.2012.347"},{"issue":"3","key":"10.1016\/j.ctrv.2016.11.011_b0320","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1200\/JCO.2015.62.9170","article-title":"Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial","volume":"34","author":"Joensuu","year":"2016","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"36","key":"10.1016\/j.ctrv.2016.11.011_b0325","doi-asserted-by":"crossref","first-page":"4276","DOI":"10.1200\/JCO.2015.62.4304","volume":"33","author":"Casali","year":"2015","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"14","key":"10.1016\/j.ctrv.2016.11.011_b0330","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1056\/NEJM200104053441404","article-title":"Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor","volume":"344","author":"Joensuu","year":"2001","journal-title":"New Engl J Med"},{"issue":"Suppl 5","key":"10.1016\/j.ctrv.2016.11.011_b0335","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1016\/S0959-8049(02)80603-7","article-title":"Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571)","volume":"38","author":"Demetri","year":"2002","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2016.11.011_b0340","unstructured":"Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004; 364(9440): p. 1127\u201334. PubMed PMID: 15451219."},{"issue":"4","key":"10.1016\/j.ctrv.2016.11.011_b0345","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1200\/JCO.2007.13.4452","article-title":"Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033","volume":"26","author":"Blanke","year":"2008","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2016.11.011_b0350","doi-asserted-by":"crossref","unstructured":"Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol: Off J Am Soc Clin Oncol 2010; 28(7): p. 1247\u201353. PubMed PMID: 20124181. Pubmed Central PMCID: 2834472. Epub 2010\/02\/04. eng.","DOI":"10.1200\/JCO.2009.24.2099"},{"issue":"23","key":"10.1016\/j.ctrv.2016.11.011_b0355","doi-asserted-by":"crossref","first-page":"4342","DOI":"10.1200\/JCO.2003.04.190","article-title":"Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor","volume":"21","author":"Heinrich","year":"2003","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"5607","key":"10.1016\/j.ctrv.2016.11.011_b0360","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1126\/science.1079666","article-title":"PDGFRA activating mutations in gastrointestinal stromal tumors","volume":"299","author":"Heinrich","year":"2003","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.ctrv.2016.11.011_b0365","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.ejca.2006.01.030","article-title":"KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours","volume":"42","author":"Debiec-Rychter","year":"2006","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.ctrv.2016.11.011_b0370","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.ejca.2003.11.025","article-title":"Use of c-KIT\/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group","volume":"40","author":"Debiec-Rychter","year":"2004","journal-title":"Eur J Cancer"},{"issue":"18","key":"10.1016\/j.ctrv.2016.11.011_b0375","doi-asserted-by":"crossref","first-page":"5749","DOI":"10.1158\/1078-0432.CCR-08-0533","article-title":"Activity of dasatinib, a dual SRC\/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation","volume":"14","author":"Dewaele","year":"2008","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.ctrv.2016.11.011_b0380","doi-asserted-by":"crossref","unstructured":"Trent J. A phase II study of dasatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST). J Clin Oncol: Off J Am Soc Clin Oncol 2011; 29(Suppl, abst 10006).","DOI":"10.1200\/jco.2011.29.15_suppl.10006"},{"issue":"10","key":"10.1016\/j.ctrv.2016.11.011_b0385","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/S1470-2045(10)70222-9","article-title":"Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial","volume":"11","author":"Le Cesne","year":"2010","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2016.11.011_b0390","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1093\/annonc\/mds587","article-title":"Influence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomised, phase III trial","volume":"24","author":"Patrikidou","year":"2013","journal-title":"Ann Oncol: Off J Eur Soc Med Oncol\/ESMO"},{"issue":"5","key":"10.1016\/j.ctrv.2016.11.011_b0395","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S1470-2045(15)70105-1","article-title":"Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial","volume":"16","author":"Blay","year":"2015","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.ctrv.2016.11.011_b0400","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1200\/JCO.2008.20.4818","article-title":"Imatinib plasma levels are correlated with clinical benefit in patients with unresectable\/metastatic gastrointestinal stromal tumors","volume":"27","author":"Demetri","year":"2009","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"15","key":"10.1016\/j.ctrv.2016.11.011_b0405","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1200\/JCO.2005.05.3439","article-title":"Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors","volume":"24","author":"Raut","year":"2006","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2016.11.011_b0410","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/jso.20466","article-title":"Surgical treatment of patients with initially inoperable and\/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate","volume":"93","author":"Rutkowski","year":"2006","journal-title":"J Surg Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2016.11.011_b0415","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/00000658-200001000-00008","article-title":"Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival","volume":"231","author":"DeMatteo","year":"2000","journal-title":"Ann Surg"},{"issue":"13","key":"10.1016\/j.ctrv.2016.11.011_b0420","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1200\/JCO.2006.07.3049","article-title":"Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria","volume":"25","author":"Choi","year":"2007","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2016.11.011_b0425","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s00330-005-2647-7","article-title":"Gastrointestinal stromal tumors: CT and MRI findings","volume":"15","author":"Sandrasegaran","year":"2005","journal-title":"Eur Radiol"},{"issue":"20","key":"10.1016\/j.ctrv.2016.11.011_b0430","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.3748\/wjg.v19.i20.3108","article-title":"Rectal gastrointestinal stromal tumors: imaging features with clinical and pathological correlation","volume":"19","author":"Jiang","year":"2013","journal-title":"World J Gastroenterol: WJG"},{"issue":"8","key":"10.1016\/j.ctrv.2016.11.011_b0435","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1002\/cncr.22214","article-title":"Early effects of imatinib mesylate on the expression of insulin-like growth factor binding protein-3 and positron emission tomography in patients with gastrointestinal stromal tumor","volume":"107","author":"Trent","year":"2006","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2016.11.011_b0440","first-page":"17","article-title":"The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors","volume":"45","author":"Gayed","year":"2004","journal-title":"J Nucl Med: Off Publ, Soc Nucl Med"},{"key":"10.1016\/j.ctrv.2016.11.011_b0445","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1102\/1470-7330.2012.0013","article-title":"Consensus report on the radiological management of patients with gastrointestinal stromal tumours (GIST): recommendations of the German GIST Imaging Working Group","volume":"12","author":"Kalkmann","year":"2012","journal-title":"Cancer Imag: Off Publ Int Cancer Imag Soc"},{"issue":"12","key":"10.1016\/j.ctrv.2016.11.011_b0450","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/j.ejca.2005.04.034","article-title":"Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg","volume":"41","author":"Zalcberg","year":"2005","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2016.11.011_b0455","doi-asserted-by":"crossref","unstructured":"Vincenzi B, Nannini M, Fumagalli E, Bronte G, Frezza AM, De Lisi D, et al. Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis. Oncotarget 2015. PubMed PMID: 26416414.","DOI":"10.18632\/oncotarget.5136"},{"issue":"9","key":"10.1016\/j.ctrv.2016.11.011_b0460","first-page":"5029","article-title":"Imatinib escalation or sunitinib treatment after first-line imatinib in metastatic gastrointestinal stromal tumor patients","volume":"34","author":"Hsu","year":"2014","journal-title":"Anticancer Res"},{"issue":"5","key":"10.1016\/j.ctrv.2016.11.011_b0465","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1007\/s10637-013-9961-8","article-title":"Efficacy, safety, and pharmacokinetics of imatinib dose escalation to 800 mg\/day in patients with advanced gastrointestinal stromal tumors","volume":"31","author":"Yoo","year":"2013","journal-title":"Invest New Drugs"},{"issue":"9544","key":"10.1016\/j.ctrv.2016.11.011_b0470","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","article-title":"Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial","volume":"368","author":"Demetri","year":"2006","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ctrv.2016.11.011_b0475","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1016\/j.ejca.2009.02.011","article-title":"Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure","volume":"45","author":"George","year":"2009","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.ctrv.2016.11.011_b0480","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1093\/annonc\/mds179","article-title":"Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib","volume":"23","author":"George","year":"2012","journal-title":"Ann Oncol: Off J Eur Soc Med Oncol\/ESMO"},{"issue":"33","key":"10.1016\/j.ctrv.2016.11.011_b0485","doi-asserted-by":"crossref","first-page":"5352","DOI":"10.1200\/JCO.2007.15.7461","article-title":"Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor","volume":"26","author":"Heinrich","year":"2008","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"9863","key":"10.1016\/j.ctrv.2016.11.011_b0490","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0140-6736(12)61857-1","article-title":"Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Demetri","year":"2013","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.ctrv.2016.11.011_b0495","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1200\/JCO.2011.39.9394","article-title":"Efficacy and safety of regorafenib in patients with metastatic and\/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial","volume":"30","author":"George","year":"2012","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2016.11.011_b0500","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S1470-2045(13)70453-4","article-title":"Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial","volume":"14","author":"Kang","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2016.11.011_b0505","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ejca.2015.10.071","article-title":"Impact of imatinib rechallenge on health-related quality of life in patients with TKI-refractory gastrointestinal stromal tumours: Sub-analysis of the placebo-controlled, randomised phase III trial (RIGHT)","volume":"52","author":"Yoo","year":"2016","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1016\/j.ctrv.2016.11.011_b0510","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1002\/cncr.29220","article-title":"Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib","volume":"121","author":"Reichardt","year":"2015","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.ctrv.2016.11.011_b0515","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1007\/s10637-012-9795-9","article-title":"Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group","volume":"30","author":"Park","year":"2012","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ctrv.2016.11.011_b0520","doi-asserted-by":"crossref","unstructured":"Wiebe L, Kasza KE, Maki RG, D'Adamo DR, Chow WA, Wade III JL, et al. Activity of sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): A phase II trial of the University of Chicago Phase II Consortium. ASCO Meet Abstr 2008; 26(15_suppl): p.10502.","DOI":"10.1200\/jco.2008.26.15_suppl.10502"},{"issue":"8","key":"10.1016\/j.ctrv.2016.11.011_b0525","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1158\/1535-7163.MCT-12-0223","article-title":"Sorafenib inhibits many kinase mutations associated with drug-resistant gastrointestinal stromal tumors","volume":"11","author":"Heinrich","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ctrv.2016.11.011_b0530","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(16)00075-9","article-title":"Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial","author":"Mir","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2016.11.011_b0535","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1093\/annonc\/mdt484","article-title":"A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib","volume":"25","author":"Ganjoo","year":"2014","journal-title":"Ann Oncol: Off J Eur Soc Med Oncol\/ESMO"},{"issue":"22","key":"10.1016\/j.ctrv.2016.11.011_b0540","doi-asserted-by":"crossref","first-page":"5745","DOI":"10.1158\/1078-0432.CCR-14-1397","article-title":"Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients","volume":"20","author":"Garner","year":"2014","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"issue":"7","key":"10.1016\/j.ctrv.2016.11.011_b0545","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.ejso.2008.11.005","article-title":"Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST)","volume":"35","author":"Fiore","year":"2009","journal-title":"Eur J Surg Oncol: J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2016.11.011_b0550","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/ijc.21164","article-title":"Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib","volume":"117","author":"Bauer","year":"2005","journal-title":"Int J Cancer J Int du Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2016.11.011_b0555","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/jso.21160","article-title":"Phase II trial of neoadjuvant\/adjuvant imatinib mesylate (IM) for advanced primary and metastatic\/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132\/ACRIN 6665","volume":"99","author":"Eisenberg","year":"2009","journal-title":"J Surg Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2016.11.011_b0560","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1245\/s10434-008-0177-7","article-title":"A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis","volume":"16","author":"McAuliffe","year":"2009","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2016.11.011_b0565","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.ejso.2013.10.021","article-title":"Radiologic assessment of earliest, best, and plateau response of gastrointestinal stromal tumors to neoadjuvant imatinib prior to successful surgical resection","volume":"40","author":"Tirumani","year":"2014","journal-title":"Eur J Surg Oncol: J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2016.11.011_b0570","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.ejca.2015.05.009","article-title":"Follow-up strategies for patients with gastrointestinal stromal tumour treated with or without adjuvant imatinib after surgery","volume":"51","author":"Joensuu","year":"2015","journal-title":"Eur J Cancer"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737216301360?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737216301360?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T03:11:21Z","timestamp":1658718681000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737216301360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":114,"alternative-id":["S0305737216301360"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2016.11.011","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GEIS guidelines for gastrointestinal sarcomas (GIST)","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2016.11.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 GEIS (GRUPO ESPA?OL DE INVESTIGACION EN SARCOMAS). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}